FLR1 Antibody

What is FLI1 and what cellular role does it play?

FLI1 (Friend Leukemia Integration 1) is a member of the ETS family of DNA binding transcription factors that plays a critical role in cellular proliferation and tumorigenesis. In normal tissue, FLI1 expression is highly restricted, found primarily in endothelial cells and small lymphocytes . As a transcription factor, FLI1 regulates gene expression by binding to specific DNA sequences and influencing cellular processes related to vascular development and hematopoiesis. Its controlled expression is essential for normal endothelial function and lymphocyte development, while dysregulation can contribute to pathological conditions, particularly vascular tumors and certain sarcomas .

How is FLI1 antibody useful in distinguishing vascular tumors?

FLI1 antibody has emerged as a valuable diagnostic tool for vascular tumors due to its high sensitivity and specificity for endothelial cells. Research indicates that FLI1 expression can be detected in the majority of vascular tumors, including angiosarcomas, hemangioendotheliomas, hemangiomas, and Kaposi's sarcomas . The sensitivity and specificity of FLI1 for identifying vascular origin has been reported to equal or exceed that of established vascular markers such as CD31, CD34, and Factor VIII . Importantly, as FLI1 is a nuclear marker (rather than cytoplasmic or membranous), it offers distinct advantages by producing cleaner staining patterns without the cytoplasmic artifacts often seen with other vascular markers due to endogenous peroxidases or biotin .

What types of FLI1 antibodies are commercially available for research?

Several types of FLI1 antibodies are available for research applications:

The choice between these formats depends on the specific research application, with monoclonal antibodies providing higher specificity for targeted epitopes, while polyclonal antibodies may offer advantages in detecting denatured proteins in Western blot applications .

What tissues are recommended as positive controls for FLI1 antibody validation?

For proper validation of FLI1 antibody performance, several tissue types are recommended as positive controls:

• Normal tissues: Adrenal gland, fallopian tube, placenta, and cervix

• Pathological tissues: Angiosarcoma, primitive neuroectodermal tumor (PNET), and hemangiomas

When validating a new FLI1 antibody, examining both normal vascular endothelium and small lymphocytes within these tissues provides internal controls for appropriate nuclear staining patterns. Additionally, Jurkat human acute T cell leukemia cell line has been documented as an effective positive control for Western blot applications, showing distinct nuclear localization of FLI1 protein .

How can FLI1 antibody be used to detect the EWS-FLI1 fusion protein in Ewing's Sarcoma?

Approximately 90% of Ewing's Sarcoma/Primitive Neuroectodermal Tumors (ES/PNET) harbor a specific chromosomal translocation t(11;22)(q24;q12), resulting in the fusion of the EWS gene with FLI1 . This translocation produces an EWS-FLI1 fusion protein that functions as an aberrant transcription factor driving oncogenesis. When investigating this fusion protein:

• Sample preparation: Nuclear extraction protocols are particularly important as the fusion protein maintains nuclear localization similar to wild-type FLI1

• Antibody selection: Choose FLI1 antibodies that recognize epitopes in the C-terminal region preserved in the fusion protein

• Complementary techniques: Combine immunohistochemistry with molecular techniques (RT-PCR or FISH) for comprehensive characterization

• Western blot analysis: The fusion protein can be detected as a distinct band with slightly different molecular weight compared to wild-type FLI1 (~53 kDa)

Researchers should be aware that while FLI1 antibody can detect the fusion protein, additional molecular confirmation is typically required for definitive diagnosis of Ewing's Sarcoma.

What considerations are important when designing flow cytometry panels including FLI1 antibody?

When incorporating FLI1 antibody into multiparameter flow cytometry panels, several critical factors must be considered:

• Nuclear localization: Since FLI1 is a nuclear protein, permeabilization protocols must ensure antibody access to nuclear targets while maintaining integrity of other cellular markers

• Fluorophore selection: Match FLI1 antibody with appropriate fluorophores based on expression level principles:

  • FLI1 is relatively low-expressed in normal lymphocytes but may be overexpressed in pathological conditions

  • Low-expressed antigens should be paired with bright fluorophores and vice versa

  • Avoid fluorophores with high similarity to autofluorescence of your cells of interest

• Panel design optimization:

  • Consider spectral overlap between fluorophores to minimize data spread

  • Use appropriate blocking agents to prevent non-specific binding:

    • 10% homologous serum or commercial Fc block for human samples

    • Anti-CD16/32 for mouse samples

    • True-stain monocyte blocker for myeloid cells

• Gating strategy: Include proper nuclear markers and ensure cytometric parameters are optimized for nuclear versus cytoplasmic discrimination

This comprehensive approach ensures high-quality data acquisition and interpretation when analyzing FLI1 expression by flow cytometry.

How does machine learning enhance the interpretation of antibody-based assays including FLI1?

The implementation of machine learning approaches is revolutionizing antibody-based assays, including those involving FLI1 antibody:

• Predictive modeling: Machine learning algorithms can predict how an antibody would interact with variants not directly tested in the laboratory . For instance, computational frameworks can infer:

  • Cross-reactivity patterns

  • Binding affinities to variant epitopes

  • Expected performance across different assay conditions

• Data integration across heterogeneous studies: Recent advances allow researchers to unify datasets from different studies, even when they have examined different variants with minimal overlap . This approach transforms the data analysis paradigm from "what you see is what you get" to "what anyone sees is what everyone gets" .

• Error estimation and validation: Advanced computational approaches can quantify uncertainty in predictions, enabling researchers to determine:

  • Which predictions have highest confidence (lowest σPredict values)

  • When additional experimental validation is necessary

  • How transferable findings are between different experimental systems

• Optimization of experimental design: Machine learning can help researchers design more efficient experiments by:

  • Identifying which variants will be maximally informative

  • Quantifying the benefits of measuring each additional variant

  • Determining the minimum number of measurements needed to achieve desired confidence levels

This integration of computational methods with traditional antibody assays represents a significant advancement in the field, allowing researchers to extract more information from limited experimental data.

What is the recommended protocol for FLI1 immunohistochemistry on FFPE tissue samples?

For optimal FLI1 immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) tissues, the following methodological approach is recommended:

• Sample preparation:

  • 4-5μm thick sections on positively charged slides

  • Complete deparaffinization and rehydration

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) in citrate buffer (pH 6.0)

  • Pressure cooker method (20 minutes) typically yields superior results

• Blocking steps:

  • Endogenous peroxidase blocking with 3% hydrogen peroxide

  • Protein blocking with 5% bovine serum albumin (BSA) to minimize non-specific binding

• Primary antibody incubation:

  • Dilute mouse monoclonal anti-FLI1 antibody (clone G146-222) according to manufacturer's recommendation

  • Overnight incubation at 4°C provides optimal signal-to-noise ratio

• Detection system:

  • Polymer-based detection systems typically provide cleaner results than biotin-based systems

  • This minimizes the cytoplasmic staining artifacts mentioned in the literature

• Counterstaining and evaluation:

  • Light hematoxylin counterstain to visualize nuclei

  • Evaluate for clean nuclear staining in endothelial cells and small lymphocytes as internal controls

This protocol has been optimized to address the specific characteristics of FLI1 as a nuclear marker, avoiding the cytoplasmic artifacts sometimes encountered with other vascular markers.

What are the key troubleshooting strategies for weak or non-specific FLI1 antibody staining?

When encountering challenges with FLI1 antibody staining, systematic troubleshooting should address:

When using FLI1 antibody in flow cytometry applications, additional considerations include:

• Addition of EDTA (2-5mM) to prevent cell aggregation

• Sample filtration to prevent clogging

• Dnase addition for sticky DNA from dead cells

• Dark storage during measurements

For Western blot applications with FLI1 antibody, ensure proper nuclear extraction protocols are followed, as demonstrated in the literature showing distinct nuclear localization of the 53 kDa FLI1 protein .

How should researchers validate the specificity of FLI1 antibody for particular applications?

Comprehensive validation of FLI1 antibody specificity requires a multi-faceted approach:

• Positive and negative tissue controls:

  • Positive controls: Examine nuclear staining in endothelial cells and lymphocytes in normal tissues

  • Positive disease controls: Angiosarcoma or Ewing's sarcoma tissues

  • Negative controls: Tissues known to lack FLI1 expression

• Western blot validation:

  • Compare whole cell lysates (WCL) versus nuclear extracts

  • Confirm specific band at approximately 53 kDa as documented in the literature

  • Include subcellular fractionation to verify nuclear localization

• Antibody blocking experiments:

  • Pre-incubate antibody with recombinant FLI1 protein

  • Verify signal elimination in positive control tissues

• Orthogonal method validation:

  • Correlate protein detection with mRNA expression data

  • Compare results across multiple antibody clones targeting different epitopes

  • When possible, utilize genetic knockdown/knockout models for definitive validation

• Application-specific controls:

  • For flow cytometry: Include fluorescence-minus-one (FMO) controls

  • For IHC: Include isotype controls and absorption controls

  • For Western blot: Include recombinant protein standards

This comprehensive validation approach ensures that signals detected with FLI1 antibody genuinely represent the target protein and minimizes misinterpretation of experimental results.

What are the considerations for using Fab fragment antibodies versus full antibodies in FLI1 research?

While the search results do not specifically address Fab fragment antibodies for FLI1, the principles demonstrated with other antibodies can be applied:

• Potential advantages of Fab fragments:

  • Reduced agonist-like effects compared to full antibodies

  • The Fab fragment format contains binding sites but lacks the Fc portion, which can activate receptors or trigger unwanted biological responses

  • Smaller size can provide better tissue penetration

  • Reduced non-specific binding through elimination of Fc-mediated interactions

• Development approach:

  • Similar to the anti-FcεRIα Fab fragment antibody development described in the literature , anti-FLI1 Fab fragments could be developed through:

    • Phage display library screening

    • Biopanning against recombinant FLI1 protein

    • Selection based on specificity, affinity, and blocking capability

• Application considerations:

  • When studying transcription factor functions, Fab fragments may offer advantages in avoiding artificial activation

  • For detection purposes only, conventional antibodies may provide stronger signals and better sensitivity

• Validation requirements:

  • Direct ELISA to confirm binding to recombinant FLI1

  • Competition ELISA to verify specificity

  • Comprehensive testing against potential cross-reactive proteins

This comparative approach to antibody format selection allows researchers to make informed choices based on their specific experimental goals.